Revvity, Inc. (RVTY) Análisis de acciones

Descripción de la empresa

Revvity, Inc. operates within the healthcare sector, specifically focusing on the diagnostics and research industry, where it delivers comprehensive health sciences solutions, technologies, and services to its clientele. The company's portfolio includes a wide array of offerings such as instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services, as well as specialized assay platforms for early detection applications. With a substantial employee base of 11,000 individuals, Revvity, Inc. maintains a significant operational footprint that supports its extensive product and service lines across the global market. The company holds a market capitalization of $9.38 billion and generates annual revenue of $2.86 billion, figures that collectively indicate a large-scale market presence and substantial operational capacity within the specialized diagnostics landscape.

Salud financiera

Revvity, Inc. reported a trailing twelve-month revenue of $2.86 billion, alongside a net income of $239.88 million and an EBITDA of $840.93 million. The substantial gap between the revenue figure and the net income reveals a significant cost structure, where operating expenses, including cost of goods sold, general administrative costs, and taxes, consume a considerable portion of total sales before arriving at the final profit. The company demonstrated robust free cash flow generation of $523.28 million, which indicates strong financial flexibility to fund capital expenditures, reduce debt obligations, or pursue strategic acquisitions without relying heavily on external financing. Regarding profitability margins, the gross margin stands at 54.8%, reflecting efficient production and pricing power before operating expenses; the operating margin is 20.1%, suggesting effective cost control relative to revenue; and the profit margin reaches 8.4%, representing the final percentage of revenue converted into net earnings after all expenses. In terms of capital structure, Revvity, Inc. holds $919.86 million in cash against total debt of $3.40 billion, resulting in a debt-to-equity ratio of 46.87, which characterizes the balance sheet as leveraged rather than conservative given that debt significantly exceeds cash reserves. Liquidity is supported by a current ratio of 1.68, indicating that the company possesses sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Return on equity is recorded at 3.2% while return on assets is 2.2%, metrics that suggest management's effectiveness in generating returns on shareholder capital and utilizing the asset base, respectively, are currently at moderate levels.

Evaluación de valoración

The valuation of Revvity, Inc. is currently reflected in a trailing P/E ratio of 40.73 and a forward P/E of 13.98. The stark difference between these two metrics implies that the market expects a significant expansion in earnings growth in the coming years, which would necessitate a substantial compression in the P/E multiple to reach the forward estimate. The price-to-book ratio stands at 1.30, indicating that the stock trades at a modest premium of roughly 30% above its book value, suggesting the market assigns some intangible value to the company's brand, technology, and customer base beyond its tangible assets. Alternative valuation metrics provide further context, with a price-to-sales ratio of 3.28 and an EV/EBITDA of 14.10, figures that suggest investors are willing to pay a premium for revenue and earnings power relative to the industry average for similar diagnostic firms. Price volatility is assessed through the 52-week high of $118.30 and the 52-week low of $81.36, with the current market price situated at 41.6% below the 52-week high and 38.4% above the 52-week low. The beta value of 1.11 indicates that the stock exhibits price volatility that is slightly higher than the broader market, meaning it tends to amplify market movements by approximately 11% during periods of fluctuation.

Growth & Income

Revenue growth for the trailing twelve months is recorded at 5.9%, while earnings growth stands at 12.5%, indicating that profitability is expanding at a rate faster than top-line sales, which implies improved operational efficiency or favorable pricing dynamics. The company offers a dividend yield of 0.3% with a payout ratio of 13.6%, suggesting that the current dividend payments are highly sustainable given the low percentage of earnings being distributed to shareholders. This conservative payout strategy allows the company to retain the majority of its earnings to reinvest into research and development, expand its product portfolio, or strengthen its balance sheet rather than focusing on increasing shareholder dividends. The overall growth and income profile presents a company with moderate revenue expansion, accelerating earnings growth, and a highly sustainable, low-yield dividend policy that prioritizes capital retention and future investment opportunities over immediate income distribution to shareholders.